1,694 reports of this reaction
5.1% of all OLAPARIB reports
#3 most reported adverse reaction
NAUSEA is the #3 most commonly reported adverse reaction for OLAPARIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,694 FDA adverse event reports linking OLAPARIB to NAUSEA. This represents approximately 5.1% of all 33,417 adverse event reports for this drug.
Patients taking OLAPARIB who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among OLAPARIB users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for OLAPARIB:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,694 FDA reports for OLAPARIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 5.1% of all adverse event reports for OLAPARIB, making it one of the most commonly reported side effect.
If you experience nausea while taking OLAPARIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.